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Abstract
Multiple myeloma is a bone marrow plasma cell tumor which is supported by the external growth factors APRIL and IL-6,
among others. Recently, we identified eosinophils and megakaryocytes to be functional components of the micro-
environmental niches of benign bone marrow plasma cells and to be important local sources of these cytokines. Here, we
investigated whether eosinophils and megakaryocytes also support the growth of tumor plasma cells in the MOPC315.BM
model for multiple myeloma. As it was shown for benign plasma cells and multiple myeloma cells, IL-6 and APRIL also
supported MOPC315.BM cell growth in vitro, IL-5 had no effect. Depletion of eosinophils in vivo by IL-5 blockade led to a
reduction of the early myeloma load. Consistent with this, myeloma growth in early stages was retarded in eosinophil-
deficient DdblGATA-1 mice. Late myeloma stages were unaffected, possibly due to megakaryocytes compensating for the
loss of eosinophils, since megakaryocytes were found to be in contact with myeloma cells in vivo and supported myeloma
growth in vitro. We conclude that eosinophils and megakaryocytes in the niches for benign bone marrow plasma cells
support the growth of malignant plasma cells. Further investigations are required to test whether perturbation of these
niches represents a potential strategy for the treatment of multiple myeloma.
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Introduction
Multiple myeloma is a tumor of isotype-switched and somat-
ically mutated plasma cells [1], closely related to long-lived plasma
cells [2,3]. Similar to myeloma cells, long-lived plasma preferen-
tially home to the bone marrow [4,5]. Although some progress has
been made during the last decade with high dose chemotherapy,
autologous stem cell transplantation, novel immunomodulatory
drugs, such as Bortezomib, Carfilzomib, Lenalidomide, Pomali-
domide, multiple myeloma is still an incurable disease with a
median survival of only six years [6–11]. Myeloma develops slowly
and progresses through three stages: (I) monoclonal gammopathy
of undetermined significance (MGUS), (II) asymptomatic, or
smoldering, myeloma, and (III) symptomatic myeloma. Progres-
sion from early to late stage myeloma appears to be accompanied
by an accumulation of mutations leading to transformation of the
original plasma cell into a more aggressive tumor cell [3,12].
Interactions between myeloma cells and the bone marrow
microenvironment are important for myeloma development and
tumor progression [13,14]. Despite current therapies not being
able to efficiently eradicate multiple myeloma cells in their bone
marrow environment, primary myeloma cells hardly survive in
in vitro cell cultures and are highly susceptible to spontaneous-
and chemotherapy-induced apoptosis. But resistance to apoptosis
is inducible by addition of extrinsic survival factors, such as IL-6 or
APRIL, among others [15–18]. These cytokines also represent
major factors supporting the development and long-term survival
of plasma cells in the bone marrow [19–21]. Of note - similar to
what was observed for myeloma cells - the bone marrow
environment seem to protect long-lived plasma cells from therapy
[22]. IL-6 and APRIL are produced within specific niches that
support long-lived bone marrow plasma cells [23]. Recent
evidence provided by us and others demonstrates that these
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niches are formed by mesenchymal stromal cells together with
hematopoietic cell types, such as eosinophils and megakaryocytes
[24–26]. Evidence that normal bone marrow plasma cell
populations are supported by eosinophils and megakaryocytes
comes from the observations that the formation and/or persistence
of long-lived bone marrow plasma cells is impaired in eosinophil
deficient DdblGATA-1 mice, after antibody-mediated eosinophil
depletion, and in c-mpl KO mice exhibiting drastically reduced
megakaryocyte populations [24,25]. Moreover, long-lived plasma
cells are significantly co-localized with eosinophils and megakar-
yocytes [25,27]. The idea that eosinophils support plama cells via
direct cell-cell contact is supported by the finding that depletion of
eosinophils results in a rapid loss of plasma cells [28]. However, in
co-culture, eosinophils are able to support isolated bone marrow
plasma cells merely by soluble factors, with APRIL playing a
major role for this effect [25]. Hence, whether direct contact to
eosinophils is required for their supportive effect on plasma cells
remains to be further elucidated. Reticular stromal cells may
organize the niches supporting bone marrow plasma cells through
the high level production of CXCL12, which attracts precursors of
long-lived plasma cells, and precursors of eosinophils and
megakaryocytes[27,29–32]. Interestingly, CXCR4, the chemokine
receptor responsible for attracting these cells to these niches is also
expressed and functionally active in multiple myeloma cells [33–
36]. Notably, a recent paper reports that multiple myeloma cells
often co-localize with eosinophils in the bone marrow and that
esinophils support the proliferation of these malignant plasma cells
in co-culture [37]. Hence, it seems possible that myeloma plasma
cells are attracted to, and expand, in niches similar to those that
support benign bone marrow plasma cells.
Here, we tested this hypothesis in the novel murine
MOPC315.BM myeloma model [38]. We show that
MOPC315.BM myeloma cells resemble an aggressive tumor
stage, but are still supported by APRIL and IL-6. MOPC315.BM
myeloma cells also expressed CXCR4, which is crucial for homing
to these niches. Accordingly, mice depleted of eosinophils - the
major local source of APRIL - exhibited reduced early
MOPC315.BM myeloma load in vivo. Within the bone marrow,
MOPC315.BM myeloma cells were not found in direct contact
with eosinophils, suggesting that the supporting effect of eosino-
phils observed in this study is merely mediated by secreted factors.
In contrast, MOPC315.BM myeloma cells were noticably co-
localized with megakaryocytes, and co-cultured megakaryocytes
supported MOPC315.BM cell growth in culture. These data
indicate that even late stage myeloma cells are supported by
eosinophils and megakaryocytes, i.e. hematopoietic components of
the niches for benign bone marrow plasma cells, and that these
niches potentially represent a novel therapeutic target for the
treatment of multiple myeloma.
Materials and Methods
Mice and injections
BALB/c mice were purchased from Charles River Laboratories
(Sulzfeld, Germany). DdblGATA-1 mice were bred in the animal
facility of the University of Luebeck. These mice were carried
mutations on GATA1 promoter which inhibit auto-regulation of
GATA-1 transcriptional factor. Mice received i.v. injections of
MOPC315.BM cells (1256105 cells). Some mice received a single
injection of 1 mg anti-IL-5 blocking antibodies (TRFK-5) one day
before injection of MOPC315.BM cells. Challenged mice were
longitudinally monitored for presence of MOPC315.BM myeloma
specific anti-2,4-dinitrophenyl (DNP) IgA antibodies in sera (for
details see below: ELISA). All animal experiments were approved
by the respective local Committee on the Ethics of Animal
Experiments of the state Schleswig-Holstein (Ministerium fu¨r
Landwirtschaft, Umwelt und la¨ndliche Ra¨ume des Landes
Schleswig Holstein). All animal experiments were performed by
certified personnel and all efforts were made to minimize suffering.
Transfection and cell culture
MOPC315.BM cells were described previously [38]. This
murine myeloma cell line was GFP-labeled by retroviral transfec-
tion: A retrovirus packing cell line was generated by triple-
transfection of HEK 293 cells with the GFP-containing retroviral
vector pMSCV and the two accessory plasmids pCAGGS-VSVg
and pEQ-Pam3(-E). MOPC315.BM cells were co-cultured for 48
hours with supernatant of the retrovirus packing cell line.
Subsequently, GFP-transfected MOPC315.BM cells were isolated
by fluorescence-activated cell sorting. MOPC315.BM cells were
grown in RPMI 1640 media (Gibco) supplemented with 10% FCS
(Gibco), 0.1% Pencilllin/Streptomycin (Gibco). For investigation
of growth factor requirements, IL-5, IL-6, and APRIL were added
to MOPC315.BM cells in 96 well culture plates separately or in
combination (100 ng/ml each). After 24 hours, Cells were washed
and frequencies of living MOPC315 cells were determined by
ELISPOT for DNP-specific IgA: cells were transferred to DNP-
BSA (5 ug/ml) coated ELISPOT plates (cellulose ester–based) and
incubated for 3 hours at 37uC, 5% CO2. Plates were washed, and
goat anti-IgA-biotin was added (Southern Biotec). Plates were
washed again and SA-HRP was added. ELISPOTs were counted
after addition of ABTS.
Co-cultures
For generation of megakaryocytes, total bone marrow cells were
pre-cultured in IMDM medium containing thrombopoietin
[10 ng/ml], 10% FCS and 0.1% Pencilllin/Streptomycin. After
three days, megakaryocyte lineage cells were isolated by BSA-
density gradient and subsequent MACS sorting for CD41+ cells.
B- and T-cells were purified from spleen via MACS separation
using B cell and CD4+ T Cell isolation kits (Miltenyi Biotec),
respectively. MOPC315 (1,000 cells) and hematopoietic cells
(10,000 cells) were co-cultured in RPMI containing 1% or 10%
FCS. After two days, numbers of viable AnnexinV-, DAPI-
MOPC315 GFP+, CD138+ cells were assessed by flow cytometry
(using a MACS QUANT, Miltenyi Biotec).
ELISA
MOPC315.BM myeloma load was determined by measuring
myeloma specific anti-DNP IgA in serum by ELISA. Briefly: 96
well plates were coated with 10 mg/ml DNP-BSA/PBS (1 h/RT).
After washing the plates three times with PBS unspecific binding
was blocked (0,5% BSA/PBS; 1 h/RT). Subsequently, sera were
incubated in serial dilutions for 60 min. Then, detection antibody
biotinylated goat anti-mouse IgA was added (1 mg/ml) (South-
ernBiotech, Birmingham, USA), and later a 3000-fold dilution of
streptavidin coupled alkaline phosphatase (Roche Diagnostics
GmbH, Mannheim, Germany) and finally ALP (Roche Diagnos-
tics GmbH, Mannheim, Germany). In-between incubation steps,
plates were washed three to five times. Readout was performed on
a FLUOstar Omega Microplate Reader (BMG LABTECH
GmbH, Ortenberg, Germany); ODs were analyzed by a (5-PL)
Non-Linear Regression Curve-Fitting Model.
Histology
Femurs were fixed in 4% PFA and then incubated in increasing
concentrations of 10%, 20% and 30% sucrose over three nights.
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Femurs were embedded in Tissue-Tek medium (Sakura Finetek),
snap- frozen in liquid nitrogen, and stored at 280uC. Tissue
sections (8 mm) were prepared with a Microtome. Sections were
washed in PBS and unspecific binding was blocked by preincu-
bation with PBS/10% rat serum and anti-CD16/CD32 (clone
2.4G2; made in-house). Staining with antibodies and secondary
reagents was performed for 1 hour and 30 min at room
temperature, respectively. The following antibodies and staining
reagents were used: goat anti-GFP-FITC (Rockland), rat anti-
CD41-APC, donkey anti-Goat IgG Alexa Fluor 488 (Molecular
Probes), eosinophil specific MBP 480 (Kindly donated by Claudia
Berek). Sections were analyzed by confocal microscopy using a
Olympus IX81 microscope.
Flow cytometry
Bone marrow and spleen were mashed between two glass slides.
Single-cell suspensions were filtered through a 70 mm cell strainer
(BD Falcon) and washed twice with PBS/0.5% BSA. To block
unspecific binding, cells were incubated with anti-CD16/CD32
(clone 2.4G2; made in-house) for 5 minutes on ice. Subsequently,
Figure 1. APRIL and IL-6 support MOPC315.BM cell growth in vitro. MOPC315.BM cells were cultured in 96 well plates containing medium
supplemented with various FCS concentrations, cytokines were added alone or in combination (100 ng/ml each), as indicated. Low density cultures
originally contained one thousand cells (upper graphs). High density plates were seeded with ten thousand cells. After three days of culture, living
MOPC315.BM cells were quantified by a myeloma specific ELISPOT assay measuring anti-DNP-specific IgA. Three independent experiments were
performed. Spot forming units (SFU) from one representative experiment are shown. Each dot represents SFUs from a single well, mean +/2SEM is
shown (statistics: Mann-Whitney U test; * = P#0.05, ** = P#0.05).
doi:10.1371/journal.pone.0109018.g001
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cells were incubated with FITC labeled anti-B220 (made in-
house), CD138PE (BD) and/or anti Siglec-F-PE (BD) for 20
minutes on ice. After washing, analysis was performed by flow
cytometry (BD Biosciences LSRII).
Real-Time PCR
Expression of APRIL and IL-6 was quantified in total bone
marrow cells by real-time PCR. Briefly: cDNA was prepared with
a Sensiscript RT kit (Qiagen), added to qPCR Master Mix (Life
Technologies, Germany) and amplified using the SDS ABI 7900
system (Applied Biosystems, Darmstadt, Germany). TaqMan
probes, forward and reverse primers were designed using the
computer software CloneManager (version 7.01; Sci Ed Central).
The optimal primmer concentrations used were 500 nm each for
the forward and reverse primers and 200 nM for the TagMan
probe (biomers.net, Ulm, Germany). Primer sequences: 39 Primer
sequence for IL-6: gtgcatcatcgttgttcatac; 59 Primer sequence for
IL-6: ctcccaacagacctgtctatac; 39 Primer sequence for APRIL:
aggcacggtcaggatcagaag; 59 Primer sequence for APRIL: gcaac-
cagtacttaggcgtgg. The same batch of cDNA (20 ml) was used to
determine the cycles of threshold (ct), and the amount of the
cytokine cDNA copies were normalized to the house keeping gene
MLN51.
Statistic software
Computation and statistical analysis (Mann-Whitney U-Test or
unpaired t test, confidence interval 95%, P values) were done with
the GraphPad Prism 4 software.
Results
APRIL and IL-6 support MOPC315.BM cell growth in vitro
Injection of murine MOPC315.BM cells into BALB/c mice
results in tumor growth mainly in the bone marrow, suggesting
that this microenvironment promotes the growth of these murine
tumor plasma cells, similar to what had been observed for multiple
myeloma cells in humans. Bone marrow derived IL-6 and APRIL
have been shown to be major environmental-derived factors
supporting the growth and drug-resistance of multiple myeloma,
and also to support the survival of long-lived bone marrow plasma
cells [15,17,23,39]. In order to test whether these cytokines also
promote the growth of MOPC315.BM cells, either 103 (low
density) or 104 (high density) of these murine myeloma cells were
cultured in 96-well plates, in medium containing either 1% or 5%
FCS and with or without supplement of IL-6 and/or APRIL. After
three days of culture, living MOPC315.BM cells were quantified
by a myeloma specific anti-DNP ELISPOT assay. In low density
cultures, the numbers of viable MOPC315.BM cells were higher
in cultures containing 5% FCS compared to those with reduced
1% FCS (Figure 1). This difference of myeloma cell growth in
cultures containing different FCS concentrations was much less
pronounced in high density cultures. In low density cultures, both
the addition of IL-6 or APRIL led to increased yield of myeloma
cells three days later, regardless whether the cultures contained 1%
or 5% FCS. Similar results were observed at days one and fife
(Figure S1). Addition of IL-6 and APRIL together did not result in
increased myeloma growth compared to supplement with one
cytokine alone. In contrast, although IL-6 and APRIL supported
myeloma growth in some high density cultures, this effect was not
consistent. These results suggest that high myeloma cell density
can substitute for external growth factors, most likely by provision
of cell-cell contact or production of autocrine growth factors. This
idea is consistent with the findings that human myeloma cells and
under certain conditions even normal plasma cells can produce
autocrine growths factors, such as IL-6 and APRIL [40,41].
Together, these results indicate that MOPC315.BM cells are
supported by IL-6 and APRIL, as have been previously reported
for multiple myeloma [15,42–44]. However, MOPC315.BM
dependency on these external growth factors is lost when
MOPC315.BM cells have reached high cell densities.
MOPC315.BM cells represent an aggressive tumor stage
In order to address MOPC315.BM cell growth in vivo,
MOPC315.BM cells were injected i.v. into mice. Within five
weeks, mice that had received 500000 MOPC315.BM cells
developed a high myeloma tumor load as indicated by serial
measurement of myeloma protein in sera (Figure 2), finally
resulting in paraplegic disease due to spinal involvement. In
accordance with what has been published earlier by Hofgaard and
colleagues [38], after three weeks most MOPC315.BM cells were
found in the bone marrow, while minor populations were present
in the liver and spleen (data not shown). Both, rapid myeloma
disease development and autocrine growth in high density cultures
suggest that the MOPC315.BM model may represent an
aggressive myeloma stage. Preferential homing of MOPC315.BM
cells to the bone marrow, as well their myeloma-related growth
factor requirements at low cell densities in vitro, indicate that
MOPC315.BM represents a suitable model for analyzing the
interaction between late stage myeloma cells and their bone
marrow environment.
Early MOPC315.BM growth in vivo is reduced after
eosinophil depletion and in eosinophil deficient mice
Eosinophils are a prominent source of APRIL in the bone
marrow and have been identified as a major functional component
of the niches for long-lived plasma cells [25,26]. Antibodies
blocking the eosinophil growth factor IL-5 have been shown to
reduce eosinophil numbers in blood and tissues of mice [45], and
several therapeutic anti-human IL-5 monoclonal antibodies that
are able to reduce eosinophil counts in patients are under
development [46]. The finding that APRIL supports
MOPC315.BM growth in vitro suggests that prominent APRIL
producing cells such as eosinophils could also support
MOPC315.BM growth in vivo. In order to test this hypothesis,
mice were treated with a single high dose of one mg anti-mouse
IL-5 blocking antibody. Already one week after treatment
Figure 2. Kinetics of MOPC315.BM myeloma load. MOPC315.BM
cells were i.v. injected into BALB/c mice (500,000 cells/mouse). At the
time points indicated M315 myeloma protein specific for the hapten
DNP was measured in sera by ELISA.
doi:10.1371/journal.pone.0109018.g002
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eosinophil numbers were about 90% and 70% reduced in
peripheral blood and bone marrow, respectively (Figure 3).
Eosinopenia was maintained for at least four weeks (Figure S2).
In accordance with the idea that eaosinophils resemble a major
source of APRIL, anti-IL-5 treatment reduced the expression of
this cytokine within the bone marrow (Figure S2). In order to study
the effect of eosinophil depletion on MOPC315.BM cell growth
in vivo, MOPC315.BM cells were injected into BALB/c mice that
have been treated one week earlier with anti-IL-5. Two weeks
after MOPC315.BM injection, the myeloma load was approxi-
mately 30% reduced in anti-IL-5 treated mice, as measured by
myeloma-specific anti-DNP protein in serum (Figure 4). However,
Figure 3. Anti-IL-5 treatment efficiently depletes eosinophils from blood and bone marrow.Mice received single injections of one mg/ml
anti-IL-5 blocking antibody. Eosinophils were quantified by flow cytometry. (A) Gating strategy: cells were electronically gated through a forward
scatter (FSC)/side scatter (SSC) gate followed by exclusion of autofluorescent cells by using two irrelevant fluorescence parameters (Fl-4 and Fl-5). In
addition, doublets were excluded according to light forward scatter width (not shown). (B) Eosinophils are identified by Siglec-F expression and SSC.
Representative data are shown from blood of PBS treated control mice and mice receiving anti-IL-5 blocking antibody, as indicated. (C) Average
eosinophil frequencies in blood and bone marrow one week after injection of anti-IL-5 or control antibodies. Each dot represents the eosinophil
frequency of an individual mouse. Mean +/2 SEM are shown (statistics: Mann-Whitney U test; ** = P#0.05, *** = P#0.001).
doi:10.1371/journal.pone.0109018.g003
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at later time points no significant differences between the treated
and untreated groups were detected. Of note, IL-5 did not support
the secretion of myeloma specific anti-DNP antibodies (Figure S3).
Instead, high concentrations of IL-5 even seem to decrease the
secretion of anti-DNP in culture. Hence, excluding the possibility
that the decrease of myeloma specific protein in anti-IL-5 treated
mice was due to suppression of antibody secretion. Together, these
results suggests that IL-5 blockade can suppress the early, but not
the late MOPC315.BM growth phase in vivo. This is consistent
with the finding that MOPC315.BM cells became independent of
external growth factors at high cell densities, which was also
observed in culture. Of note, IL-5 has not been implicated as a
growth factor for myeloma cells and does not support the growth
of MOPC315.BM cells in vitro (Figure S4). These results suggest
that reduction of myeloma load after anti-IL-5 injection is due to
the depletion of eosinophils.
When the number of injected MOPC315.BM cells was reduced
to 100000 per mouse, the myeloma load increased at a lower rate
and the variation of the myeloma load within the groups became
very high. Four weeks after injection, myeloma specific anti-DNP
was present in all mice of the control group (10/10), but in only
70% (7/10) of IL-5 treated mice (Table 1). Consistent with the
effect of anti-IL-5 blocking antibodies on the myeloma load after
injection of high numbers of MOPC315.BM cells, eosinophil-
depletion showed its capacity to reduce early myeloma growths.
In order to probe this idea further MOPC315.BM cells were
injected into DdblGATA-1 deficient mice. These mice exhibit an
eosinophil deficiency but otherwise a normal hematopoiesis. Most
likely as a consequence of the absence of eosinophils, APRIL levels
are severely reduced within the bone marrow of such mice [25].
Before injection, MOPC315.BM cells were retrovirally transfected
with eGFP, allowing for the identification by flow cytometry. In
culture, transfected MOPC315.BM cells were supported by
APRIL and IL-6 similar to non-transfected cells (data not shown).
When mice were analyzed two weeks after injection, DdblGATA-1
mice showed an approximately 60% reduction in the frequencies
of MOPC315.BM cells in the bone marrow compared to control
mice (Figure 4). Noteworthy, eGFP-transfected MOPC315.BM
cells homed not only to the bone marrow, but to an increased
extent also to other tissues. Similar to what have been reported for
‘‘normal’’ plasma cells, MOPC315.BM loads were reduced in the
bone marrow but not in other tissues of DdblGATA-1 deficient
mice. These results suggest that eosinopenia specifically impairs
the myeloma supporting capacity of the niches in bone marrow.
Together, these data indicate that depletion of eosinophils - either
by anti-IL-5 or in genetically modified mice - impairs the growth
of MOPC315.BM myeloma cells in the bone marrow during early
myeloma development.
Megakaryocytes support MOPC315.BM myeloma cell
growth in co-culture
Megakaryocytes represent another hematopoietic cell type that
contributes to the niches supporting benign long-lived bone
marrow plasma cells [24,27]. Megakaryocytes constitutively
produce IL-6, a major growth factor for both benign and
malignant plasma cells. Unfortunately, the MOPC315.BM model
is derived from BALB/c mice and is not compatible with existing
mouse models exhibiting specifically and massively reduced
megakaryopoiesis, such as c-mpl KO mice. Therefore, the
potential supportive role of megakaryocytes for MOPC315.BM
myeloma cell growth was investigated in an in vitro co-culture
setting. Myeloma cells were seeded in low density cultures as
described above, together with various cell types in ratios of 10 to 1
(feeder cell to myeloma cell). In cultures supplemented with 1%
FCS, in vitro-generated and purified CD41+ megakaryocyte
lineage cells resulted in an approximately 2 to 6-fold increase in
myeloma cell numbers compared to myeloma cells cultured
without feeder cells (Figure. 5). B cells or CD4+ T cells had no
effect. In the presence of 10% FCS, that boosted growth of
MOPC315.BM, megakaryocyte lineage cells had no additional
effect on myeloma cell growth. These data demonstrate that
megakaryocytes exhibit a supportive effect on myeloma cell
growth. These observations are in accordance with the idea that
hematopoietic components of the niches for benign plasma cells
can also support the growth of myeloma cells, although this effect
might be relevant only under suboptimal conditions, i.e. low cell
density culture or low frequency among total bone marrow cells
during the early growth phase in vivo.
MOPC315.BM myeloma cells co-localize with
megakaryocytes in the bone marrow
The chemokine receptor CXCR4 is crucial for the homing of
long-lived plasma cells to the bone marrow niches [47–49]. The
CXCL12/CXCR4 axis can also recruit precursors of eosinophils
and megakaryocytes to the CXCL12-producing stromal cells that
seem to form the scaffold of the plasma cell supporting bone
marrow niche [27]. Similarly, CXCR4 has also been implicated in
the bone marrow specific homing capacities of multiple myeloma
cells [50]. Flow cytometric analysis revealed that this chemokine
receptor is also expressed on MOPC315.BM cells (data not
shown). In order to investigate whether indeed MOPC315.BM
cells preferentially home into the same micro-environmental
niches that support the survival of long-lived plasma cells, the
cellular environments of eGFP-labeled MOPC315.BM cells were
analyzed by confocal microscopy. During later stages of myeloma
growth – typically starting from three to four weeks after injection -
MOPC315.BM cells occupied a significant proportion of the
whole bone marrow, which made co-localization studies difficult
(data not shown). At earlier time points myeloma cells were often
Table 1. Impact of anti-IL-5 treatment on incidence of early myeloma development.
no of mice exhibiting no
detectable myeloma load
no of mice with low
myeloma load
no of mice with intermediate
myeloma load
no of mice with high
myeloma load
control group 0 3 4 3
anti-Il-5 treated group 3 3 3 1
MOPC315 BM. cells were injected at low doses (one hundred thousand per mouse). Anti-IL-5 blocking antibody or PBS (control) was injected one day before injection of
the myeloma cells. Myeloma specific anti-DNP in serum was quantified as a measure for the myeloma load. Data shown represent myeloma load at day 28 after injection
of MOPC315 BM. Cells. Detection limit = 2 units anti-DNP; low myeloma load = between 2 and 50 units anti-DNP; intermediate myeloma load =between 50 and 100 units
anti-DNP; high myeloma load = above 100 units anti-DNP.
doi:10.1371/journal.pone.0109018.t001
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hard to detect, while samples exhibiting intermediate myeloma
load were very rare. These observations suggest that the early
phase is characterized by only a few myeloma cells in bone
marrow that do not significantly expand for approximately two-to-
three weeks. This phase seems to be followed by a short phase of
rapid expansion of myeloma cells. However, this issue needs
further investigation.
In samples of femurs exhibiting an intermediate myeloma load
where individual myeloma cells and small clusters of myeloma cells
were detectable, co-localization between myeloma cells, MBP+
eosinophils and CD41+ megakaryocyte lineage cells was studied.
Of a total of more than 1200 eGFP-labeled MOPC315.BM cells
from femurs of three mice analyzed, approximately 2.9% of
myeloma cells were co-localized with eosinophils (Figure 6). This is
much below the 60% of long-lived plasma cells that has been
previously reported to co-localize with eosinophils [25]. The low
co-localization between MOPC315.BM cells and eosinophils
indicates that the observed eosinophil-mediated support of
MOPC315.BM cells may not require direct cell-cell contact. This
finding is in accordance with the observations that eosinophil
deficiency in DdblGATA-1 mice results in a severe reduction of
APRIL expression and that eosinophil support of long-lived
plasma cells and myeloma plasma cells is mediated by soluble
factors [25,37]. Contacts between MOPC315.BM cells and
megakaryocytes were approximately 12-times more frequent than
Figure 4. Eosinopenia impairs MOPC315.BM myeloma growth
in vivo. (A) In order to induce eosinopenia mice were treated with anti-
IL-5 blocking antibody. One week later, 56105 MOPC315.BM cells were
injected and myeloma load was determined by quantification of
myeloma-specific serum protein (anti-DNP) by ELISA. Each dot
represents myeloma specific protein from one mouse at week two
after myeloma cell injection (statistics: unpaired t-test; * = P#0.05). (B)
Top: Example of flow cytometric analysis of CD138, B220 and GFP
expression in bone marrow of mice that four weeks earlier received
either MOPC315.BM transfected with eGFP, or PBS (control). MOPC315
cells were identified according their high level expression of GFP (as
indicated by quadrant). Bottom: eGFP-labeled MOPC315.BM cells were
injected into eosinophil deficient DdblGATA-1 mice and wild type mice,
both on a BALB/c background. Two weeks after injection, eGFP-labeled
myeloma cells were quantified in the bone marrow by flow cytometry.
Each dot represents MOPC315.BM counts in one mouse. Data shown in
part A and B represent data from two independent experiments. Mean
+/2 SD are shown (statistics: Mann-Whitney U test; * = P#0.05).
doi:10.1371/journal.pone.0109018.g004
Figure 5. MOPC315.BM myeloma cell growth is supported by
co-cultured megakaryocytes. MOPC315.BM cells were cultured at
low densities (1000 cells/well) in 96 well plates alone (MM) or together
with in vitro-generated megakaryocytes (MK), CD4+ T cells (TC) or IgD+
B cells (BC) in medium supplemented with either 1% or 10% FCS, as
indicated. Ratio of myeloma cells to feeder cells was 1:10. After two
days of culture the numbers of viable (AnnexinV-, DAPI-) MOPC315.BM
cells (GFP+, CD138+) were quantified by flow cytometry. Each dot
represents myeloma cell counts from a single well. Data are
representative for four independent experiments. Mean +/2 SEM are
shown (statistics: Mann-Whitney U test; * = P#0.05).
doi:10.1371/journal.pone.0109018.g005
PC Niches Support Myeloma Growth
PLOS ONE | www.plosone.org 7 October 2014 | Volume 9 | Issue 10 | e109018
Figure 6. MOPC315.BM myeloma cells co-localize with megakaryocytes in vivo. Cryosections of murine bone marrow (femur) from mice
with moderate load of eGFP-labelled MOPC315 BM cells. (A) Sections were stained for eosinophils (MBP, red) megakaryocytes (CD41, white).
MOPC315 BM cells were identified by eGFP (green). Analysis was performed with a Olympus IX81 confocal microscope using a 20x oil objective and
processed with Olympus microscope and Adobe Photoshop software. Left: representative picture from a femur exhibiting intermediate myeloma
load. Right: myeloma cells often make direct contact to megakaryocytes. (B) In femurs of three mice a total of 1244 MOPC315.BM myeloma cells were
screened for their contacts to MBP+ eosinophils and CD41+ megakaryocytes, respectively. Contacts to CD41+ ‘‘particles’’ which could not clearly
morphologically identified as a megakaryocyte were counted separately. Left: Bars show the respective co-localization frequencies for myeloma cells
Right: Contact frequencies normalized on the total cell surface areas of megakaryocytes and eosinophils, respectively. Normalized data presented as
contacts of one hundred myeloma cell to one square micrometer of the respective niche cell. One experiment was performed. Mean +/2 SD are
shown (statistics: Mann-Whitney U test; * = P#0.05).
doi:10.1371/journal.pone.0109018.g006
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contacts between MOPC315.BM cells and eosinophils (Figure 6).
These contact frequencies were normalized for the total cell
surface areas of megakaryocytes and eosinophils which provide a
measure for their relative contact probabilities, as described earlier
[24]. The normalized contact frequencies per cell surface area
were approximately 10-times higher for MOPC315.BM cell
contacts to megakaryocytes compared to contacts to eosinophils.
This result shows that the contacts between MOPC315.BM cells
and megakaryocytes are much more frequent than expected in a
setting where both cell types are randomly distributed, possibly
suggesting that MOPC315.BM cells and megakaryocytes are
attracted to the same niche. Of note, another 22.6% of
MOPC315.BM cells were found in contact with ‘‘particles’’ that
stained for the megakaryocyte lineage marker CD41, but could
not be clearly identified as megakaryocytes on the basis of
morphology. Whether these contacts indicate previous interaction
to megakaryocytes needs to be elucidated.
Discussion
Multiple myeloma is a so far incurable tumor of bone marrow
plasma cells. Here, we report that murine MOPC315.BM
myeloma cells have similar growth factor requirements and
homing capacities as multiple myeloma cells and therefore
represent a suitable model for studying the interaction of myeloma
cells with the micro-environmental niches for normal plasma cells.
The data presented indicate that the hematopoietic components of
these niches – eosinophils and megakaryocytes –support also the
growth of MOPC315.BM myeloma cells.
Notably, IL-5 blockade-mediated eosinophil depletion reduced
the early myeloma load, providing a proof of principle that
therapeutic targeting of hematopoietic components of plasma cell
niches represents a novel strategy for suppressing multiple
myeloma. Although the therapeutic effect of eosinophil depletion
in the MOPC315.BM myeloma model is not pronounced, it is still
remarkable because MOPC315.BM myeloma cells resemble a late
and aggressive tumor stage.
When cultured in higher densities in medium supplemented by
high FCS concentrations, MOPC315.BM myeloma cells did not
require any external stimulation by APRIL or IL-6. Such a growth
behavior is similar to that observed for myeloma cell lines
resembling late stage tumors but differs from that of primary
myeloma cells, which exhibit stronger dependency on external
stimulation [51]. Primary multiple myeloma cells derived from
patients might be more closely related to untransformed benign
bone marrow plasma cells than MOPC315.BM myeloma cells. In
accordance with this, Wong and colleagues recently described that
multiple myeloma cells often co-localize with eosinophils in vivo,
similar to what has been previously described for benign bone
marrow plasma cells [37]. The same study also showed that
eosinophils support the growth of multiple myeloma cells in vitro
via secretion of soluble factors and suggested an IL-6 independent
mechanism of supporting of myeloma cell growth. The findings
presented in our study suggest that decreased APRIL and IL-6
production likely contributes to the reduced MOPC315 growth
observed in DdblGATA-1 mice and after IL-5 treatment.
However, suppression of other eosinophil derived myeloma
growth factors might be also involved. Whether eosinophils and
megakaryocytes express other prominent myeloma growth factors
such as insulin-like growth factor type 1 (IGF-1) [52,53], needs to
be elucidated. Clearly, individual components of the niche can
produce multiple important myeloma growth factors. Therefore,
we propose that targeting of niche cells might be a more efficient
strategy to suppress myeloma growth than blockade of individual
growths factors.
Together, multiple myeloma cells and cells of the
MOPC315.BM model are supported by eosinophils-derived
factors but only the former are often directly co-localized to
eosinophils. Hence, again suggesting that MOPC315.BM cells
resemble a late stage tumor and that most multiple myeloma –
particularly during the early stage of disease - are likely to be more
affected by eosinophil depletion than what we observed in this late
stage tumor model. Therefore, we conclude that treatment of early
stage multiple myeloma with anti-IL-5 blocking reagents is worth a
trial in patients. Multiple anti-human IL-5 blocking reagents are
under development for the treatment of eosinophilic conditions
and initial studies indicate that these biologicals are well tolerated
[54,55].
At least in culture, addition of APRIL and IL-6 together did not
support myeloma growth above that of the single factors added
alone, suggesting that the two cytokines exhibit redundant effects
for supporting myeloma growth. Other factors such as IGF-1 are
also important for myeloma growth in vivo [52,53]. These
observations may explain why IL-6 depletion did not turn out to
be very effective for the treatment of myeloma patients, and
suggests that targeting of the niche cells that simultaneously
provide several myeloma supporting factors could be more
effective.
Whether eosinophils represent the most important niche cells
supporting myeloma growth needs to be elucidated. The
observations that megakaryocytes represent an important source
of IL-6 [24], support MOPC315.BM myeloma cells in co-culture,
and are co-localized with MOPC315.BM myeloma cells in vivo,
suggest that megakaryocytes can substitute for the supportive effect
of eosinophils on myeloma growth in the bone marrow. Therefore,
an optimal strategy for blocking the supportive effect of plasma cell
niches on myeloma growth may require combined targeting of
multiple niche components, such as eosinophils and megakaryo-
cytes at the same time.
Supporting Information
Figure S1 Kinetics of APRIL mediated support of
MOPC315.BM cell growth in vitro. MOPC315.BM cells
were cultured in 96 well plates containing medium supplemented
with 5% FCS concentrations, as described in Figure 1. After one,
three and fife days of culture, living MOPC315.BM cells were
quantified by a myeloma specific ELISPOT assay measuring anti-
DNP-specific IgA. One experiment was performed. SFU=Spot
forming units (SFU). Each dot represents SFUs from a single well,
mean +/2SEMSD is shown (statistics: Mann-Whitney U test;
** = P#0.05).
(TIF)
Figure S2 Eosinophil depletion by anti-IL-5. Mice re-
ceived a single injection of 1 mg anti IL-5 blocking antibody
(TRFK-5) or PBS. (A) Subsequently, eosinophil frequencies were
analysed in blood by flow cytometry, at the time points indicated.
Each spot resembles the average of three individuals. (B) At day
seven after injection of anti-IL-5 antibodies, expression of APRIL
mRNA and IL-6 mRNA by total bone marrow cells were
quantified by RT-PCR. RU= relative units. Statistics: Mann-
Whitney U Test; * = P#0.05. Data are representative of one
experiment with three mice per group. Mean +/2 SD are shown.
(TIF)
Figure S3 Effect of IL-5 on the production of myeloma
specific protein. MOPC315.BM cells were cultured in 96 well
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plates containing medium supplemented with 1% FCS concen-
trations, as described in the methods section. IL-5 was added every
other day. Myeloma specific anti-DNP IgA in supernatants from
days three, fife and seven was measured by ELISA as described in
the methods section. Each dot represents a single well. Statistics:
Mann-Whitney U Test; * = P#0.05.
(TIF)
Figure S4 IL-5 does not support the growth of
MOPC315.BM cells. MOPC315.BM cells were cultured in 96
well plates in high density cultures as described in Figure 1, with
medium supplemented with 5% FCS. IL-5 was added at 100 ng/
ml, control wells received no cytokine (NC). After three days of
culture, living MOPC315.BM cells were quantified by a myeloma
specific ELISPOT assay measuring anti-DNP-specific IgA. Each
dot represents the number of spot forming units (SFU) from a
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